Indeed, clinical experience with SNS-032 in patients with chronic lymphocytic leukemia and multiple myeloma identified neutropenia as the dose-limiting side-effect, thought to be a consequence of decreased expression of Mcl-1 and XIAP [71]. Here, XIAP is linked to AL amyloidosis.